Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Kylix describes new Tie-2/KDR inhibitors and their use

Sep. 5, 2003

Avidex and Dow to develop biotargeted radiopharmaceuticals for cancer

Sep. 5, 2003

Satraplatin phase III trial cleared to begin

Sep. 4, 2003

TLK-286 awarded fast track status for advanced ovarian cancer

Sep. 4, 2003

Cathepsin B as a therapeutic target in cancer and arthritis

Sep. 4, 2003

Novel CDK inhibitors described in recent Warner-Lambert patent

Sep. 3, 2003

Daiichi discontinues development of DE-310

Sep. 2, 2003

New MEK inhibitors and their use patented

Sep. 2, 2003

PSA-activated thapsigargin prodrug as a specific agent for prostate cancer

Sep. 2, 2003

JIMB-01, a microtubule-modifying agent, has antiproliferative properties in human malignant tumors

Sep. 2, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...